Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

V. Di Marco, L. Covolo, V. Calvaruso, M. Levrero, M. Puoti, F. Suter, G. B. Gaeta, C. Ferrari, G. Raimondo, G. Fattovich, T. Santantonio, A. Alberti, R. Bruno, C. Mussini, M. Mondelli, F. Donato, A. Craxì

Research output: Contribution to journalArticle

Abstract

We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naïve patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09-4.30; P = 0.039) and C/C genotype rs12979860 SNP (OR 2.83; 1.19-6.74; P = 0.002) in 163 females, while absence of visceral obesity (OR 2.491; 1.131-5.487; P = 0.023), HCV-RNA lower than 400 000 IU/mL (OR 2.66; 1.273-5.558; P = 0.009) and C/C genotype rs12979860 SNP (OR 4.969; 2.401-10.283; P <0.001) were independently associated with SVR in 199 males. Combining favourable baseline variables, the probability of obtaining SVR ranged from 27.6% to 84.2% in females, and from 14.3% to 85.7% in males. The rate of SVR was 81.1% in 175 genotype 2 patients, and 69% in 100 genotype 3 patients. Rapid virologic response was the only valid predictor of SVR regardless of other features. In conclusions, in the setting of HCV genotype 1, chronic hepatitis, combining rapid virologic response and predictive factors, which are different for females and males, allows clinicians to single out a group of patients whose likelihood of SVR exceeds 80%. For these patients, triple therapy with first-generation protease inhibitors may be unwarranted.

Original languageEnglish
Pages (from-to)790-800
Number of pages11
JournalJournal of Viral Hepatitis
Volume20
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Genotype
Hepacivirus
Therapeutics
Single Nucleotide Polymorphism
Sustained Virologic Response
Abdominal Obesity
Chronic Hepatitis
Protease Inhibitors
Logistic Models
Regression Analysis
Demography
RNA

Keywords

  • chronic hepatitis C
  • gender
  • HCV-RNA levels
  • IL28B polymorphisms
  • peg-interferon and ribavirin
  • sustained virologic response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. / Di Marco, V.; Covolo, L.; Calvaruso, V.; Levrero, M.; Puoti, M.; Suter, F.; Gaeta, G. B.; Ferrari, C.; Raimondo, G.; Fattovich, G.; Santantonio, T.; Alberti, A.; Bruno, R.; Mussini, C.; Mondelli, M.; Donato, F.; Craxì, A.

In: Journal of Viral Hepatitis, Vol. 20, No. 11, 2013, p. 790-800.

Research output: Contribution to journalArticle

Di Marco, V, Covolo, L, Calvaruso, V, Levrero, M, Puoti, M, Suter, F, Gaeta, GB, Ferrari, C, Raimondo, G, Fattovich, G, Santantonio, T, Alberti, A, Bruno, R, Mussini, C, Mondelli, M, Donato, F & Craxì, A 2013, 'Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis', Journal of Viral Hepatitis, vol. 20, no. 11, pp. 790-800. https://doi.org/10.1111/jvh.12106
Di Marco, V. ; Covolo, L. ; Calvaruso, V. ; Levrero, M. ; Puoti, M. ; Suter, F. ; Gaeta, G. B. ; Ferrari, C. ; Raimondo, G. ; Fattovich, G. ; Santantonio, T. ; Alberti, A. ; Bruno, R. ; Mussini, C. ; Mondelli, M. ; Donato, F. ; Craxì, A. / Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. In: Journal of Viral Hepatitis. 2013 ; Vol. 20, No. 11. pp. 790-800.
@article{e344750840f3499db89f264416661a38,
title = "Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis",
abstract = "We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy na{\"i}ve patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44{\%}), and SVR was independently associated with age less than 50 years (OR 2.12; 95{\%} CI 1.09-4.30; P = 0.039) and C/C genotype rs12979860 SNP (OR 2.83; 1.19-6.74; P = 0.002) in 163 females, while absence of visceral obesity (OR 2.491; 1.131-5.487; P = 0.023), HCV-RNA lower than 400 000 IU/mL (OR 2.66; 1.273-5.558; P = 0.009) and C/C genotype rs12979860 SNP (OR 4.969; 2.401-10.283; P <0.001) were independently associated with SVR in 199 males. Combining favourable baseline variables, the probability of obtaining SVR ranged from 27.6{\%} to 84.2{\%} in females, and from 14.3{\%} to 85.7{\%} in males. The rate of SVR was 81.1{\%} in 175 genotype 2 patients, and 69{\%} in 100 genotype 3 patients. Rapid virologic response was the only valid predictor of SVR regardless of other features. In conclusions, in the setting of HCV genotype 1, chronic hepatitis, combining rapid virologic response and predictive factors, which are different for females and males, allows clinicians to single out a group of patients whose likelihood of SVR exceeds 80{\%}. For these patients, triple therapy with first-generation protease inhibitors may be unwarranted.",
keywords = "chronic hepatitis C, gender, HCV-RNA levels, IL28B polymorphisms, peg-interferon and ribavirin, sustained virologic response",
author = "{Di Marco}, V. and L. Covolo and V. Calvaruso and M. Levrero and M. Puoti and F. Suter and Gaeta, {G. B.} and C. Ferrari and G. Raimondo and G. Fattovich and T. Santantonio and A. Alberti and R. Bruno and C. Mussini and M. Mondelli and F. Donato and A. Crax{\`i}",
year = "2013",
doi = "10.1111/jvh.12106",
language = "English",
volume = "20",
pages = "790--800",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

TY - JOUR

T1 - Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

AU - Di Marco, V.

AU - Covolo, L.

AU - Calvaruso, V.

AU - Levrero, M.

AU - Puoti, M.

AU - Suter, F.

AU - Gaeta, G. B.

AU - Ferrari, C.

AU - Raimondo, G.

AU - Fattovich, G.

AU - Santantonio, T.

AU - Alberti, A.

AU - Bruno, R.

AU - Mussini, C.

AU - Mondelli, M.

AU - Donato, F.

AU - Craxì, A.

PY - 2013

Y1 - 2013

N2 - We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naïve patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09-4.30; P = 0.039) and C/C genotype rs12979860 SNP (OR 2.83; 1.19-6.74; P = 0.002) in 163 females, while absence of visceral obesity (OR 2.491; 1.131-5.487; P = 0.023), HCV-RNA lower than 400 000 IU/mL (OR 2.66; 1.273-5.558; P = 0.009) and C/C genotype rs12979860 SNP (OR 4.969; 2.401-10.283; P <0.001) were independently associated with SVR in 199 males. Combining favourable baseline variables, the probability of obtaining SVR ranged from 27.6% to 84.2% in females, and from 14.3% to 85.7% in males. The rate of SVR was 81.1% in 175 genotype 2 patients, and 69% in 100 genotype 3 patients. Rapid virologic response was the only valid predictor of SVR regardless of other features. In conclusions, in the setting of HCV genotype 1, chronic hepatitis, combining rapid virologic response and predictive factors, which are different for females and males, allows clinicians to single out a group of patients whose likelihood of SVR exceeds 80%. For these patients, triple therapy with first-generation protease inhibitors may be unwarranted.

AB - We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naïve patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09-4.30; P = 0.039) and C/C genotype rs12979860 SNP (OR 2.83; 1.19-6.74; P = 0.002) in 163 females, while absence of visceral obesity (OR 2.491; 1.131-5.487; P = 0.023), HCV-RNA lower than 400 000 IU/mL (OR 2.66; 1.273-5.558; P = 0.009) and C/C genotype rs12979860 SNP (OR 4.969; 2.401-10.283; P <0.001) were independently associated with SVR in 199 males. Combining favourable baseline variables, the probability of obtaining SVR ranged from 27.6% to 84.2% in females, and from 14.3% to 85.7% in males. The rate of SVR was 81.1% in 175 genotype 2 patients, and 69% in 100 genotype 3 patients. Rapid virologic response was the only valid predictor of SVR regardless of other features. In conclusions, in the setting of HCV genotype 1, chronic hepatitis, combining rapid virologic response and predictive factors, which are different for females and males, allows clinicians to single out a group of patients whose likelihood of SVR exceeds 80%. For these patients, triple therapy with first-generation protease inhibitors may be unwarranted.

KW - chronic hepatitis C

KW - gender

KW - HCV-RNA levels

KW - IL28B polymorphisms

KW - peg-interferon and ribavirin

KW - sustained virologic response

UR - http://www.scopus.com/inward/record.url?scp=84885444266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885444266&partnerID=8YFLogxK

U2 - 10.1111/jvh.12106

DO - 10.1111/jvh.12106

M3 - Article

C2 - 24168258

AN - SCOPUS:84885444266

VL - 20

SP - 790

EP - 800

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 11

ER -